Australian biotech market watch 28/09/09
Monday, 28 September, 2009
The ASX200 opened sharply lower as expected, and was sitting at 4659 at 11:00am.
Among the pharmaceutical stocks, market heavyweight CSL Limited (ASX:CSL) was down 52c to $33.85
Photoprotective drug manufacturer, Clinuvel Pharmaceuticals (ASX:CUV) slumped nearly 6% to 31.5c after releasing its full year financial results – a 32% drop in revenues and a loss of $15.3M
Cellistis Limited (ASX:CST) fared little better, dropping 12c to $3.25 despite its recent announcement of a record $8.2M annual profit. The Cellistis share price had recently spiked as high as $4.00 and had more than tripled since February.
More positive numbers for Acrux (ASX:ACR) up almost 5% to $1.58 and Chemgenex (ASX:CXS) up almost 4% to 78.5c
Maternal diet doesn't affect baby's food allergy risk
Higher maternal consumption of egg and peanut during pregnancy and breastfeeding does not protect...
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
